Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 10:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2665–2688 of 14,150 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
Interventions: Placebo Matching Mitapivat, Mitapivat; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 6
States / cities: La Jolla, California • Palo Alto, California • Boston, Massachusetts + 3 more

Conditions: Alzheimer Disease
Interventions: ADEL-Y01 - healty participants, Placebo - Healthy Participants, ADEL-Y01 - MCI/AD, Placebo - MCI/AD; Drug
Lead sponsor: Alzheimer's Disease Expert Lab (ADEL), Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Anaheim, California • Lady Lake, Florida • Maitland, Florida + 3 more

Conditions: Diabetic Neuropathic Pain
Interventions: ABT-639, pregabalin, Placebo; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 19
States / cities: Little Rock, Arkansas • Anaheim, California • Long Beach, California + 15 more

Conditions: Duchenne Muscular Dystrophy
Interventions: SRP-4045, SRP-4053, Placebo; Drug
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 6 Years to 13 Years · Male only
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 23
States / cities: Phoenix, Arizona • Los Angeles, California • San Diego, California + 19 more

Conditions: Geographic Atrophy, Macular Degeneration
Interventions: Avacincaptad Pegol, Sham; Drug
Lead sponsor: IVERIC bio, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 96
States / cities: Beverly Hills, California • Campbell, California • Fresno, California + 86 more

Conditions: Systemic Sclerosis
Interventions: RO7303509, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Palo Alto, California • New York, New York • Dallas, Texas

Conditions: Sexual Dysfunction, Psychological
Interventions: Non-prescription Zestra(TM): patented formulation; Drug
Lead sponsor: QualiLife Pharmaceuticals; Industry
Eligibility: 21 Years to 65 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 13
States / cities: Tarzana, California • Aurora, Colorado • Aventura, Florida + 10 more

Conditions: Abuse, Child, Crying, Parent-Child Relations
Interventions: Take 5 and Audio Clip, Take 5 Only; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Choroideremia
Interventions: BIIB111; Genetic
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 8
States / cities: Los Angeles, California • Miami, Florida • Baltimore, Maryland + 5 more

Conditions: Healthy
Interventions: azelaic acid pre-foam formulation, Vehicle pre-foam formulation, Water, Sodium lauryl sulfate; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Pain
Interventions: Percutaneous radiofrequency electrical nerve stimulation, Non-therapeutic stimulation; Device
Lead sponsor: Synaptrix, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Daphne, Alabama • Williamsville, New York • Chapel Hill, North Carolina + 2 more

Conditions: Hypertension, Pulmonary
Interventions: Selexipag, Placebo, Standard of Care (SOC): Endothelin receptor antagonist, SOC: Phosphodiesterase type 5 (PDE-5) inhibitor, SOC: Soluble guanylate cyclase stimulator; Drug
Lead sponsor: Actelion; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 13
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more

Conditions: Osteoarthritis, Knee
Interventions: Celecoxib, Placebo; Drug · Other
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 388 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 33
States / cities: Birmingham, Alabama • Buena Park, California • Denver, Colorado + 28 more

Conditions: Antipsychotic-induced Weight Gain (AIWG)
Interventions: Miricorilant, Placebo; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 27
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Culver City, California + 23 more

Conditions: Childhood Obesity
Interventions: Education Home Visits; Other
Lead sponsor: Arizona State University; Other
Eligibility: 1 Day to 40 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: PG324 Ophthalmic Solution 0.01%, PG324 Ophthalmic Solution 0.02%, Netarsudil (AR-13324) Ophthalmic Solution 0.02%, Latanoprost Ophthalmic Solution 0.005%; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 23
States / cities: Artesia, California • Inglewood, California • Newport Beach, California + 20 more

Conditions: HIV Infections
Interventions: GSK3732394, Placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetic Foot Ulcers
Interventions: DSC127, placebo vehicle gel, Standard of Care gel, Aquasite; Drug
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 33
States / cities: Mesa, Arizona • Phoenix, Arizona • Castro Valley, California + 25 more

Conditions: Diabetes Mellitus
Interventions: BGP-15 100 mg QD, BGP-15 100 mg BID, Placebo BID, BGP-15 200 mg QD, BGP-15 200 mg BID, BGP-15 400 mg QD; Drug
Lead sponsor: N-Gene Research Laboratories, Inc.; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 20
States / cities: Los Angeles, California • Paramount, California • Tustin, California + 17 more

Conditions: Constipation Predominant Irritable Bowel Syndrome
Interventions: Tenapanor, Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 111
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 92 more

Conditions: Muscle Spasticity, Multiple Sclerosis
Interventions: incabotulinumtoxinA, Placebo; Biological
Lead sponsor: Multiple Sclerosis Center of Northeastern New York; Other
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Latham, New York

Conditions: Asthma
Interventions: Indacaterol maleate, Indacaterol acetate, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: North Dartmouth, Massachusetts • St Louis, Missouri • Skillman, New Jersey + 3 more

Conditions: Meconium Aspiration
Interventions: Lucinactant, Standard Care; Drug · Other
Lead sponsor: Windtree Therapeutics; Industry
Eligibility: Up to 48 Hours
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Warrington, Pennsylvania

Conditions: Colitis, Ulcerative
Interventions: Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Placebo; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 32
States / cities: Litchfield Park, Arizona • Apple Valley, California • Lancaster, California + 26 more

Search by objective public record fields.

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)

A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01

A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain

Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)

A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis

Zestra in Women With Mixed Sexual Dysfunction

Take 5 + Audio Clip Randomized Control Trial

Efficacy and Safety of BIIB111 for the Treatment of Choroideremia

21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation

Pivotal Study on the NOVABLOC System for Patients Undergoing Primary Total Knee Arthroplasty

A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

Safety and Efficacy of Celecoxib Versus Placebo in the Treatment of Knee Osteoarthritis in Patients Who Were Unresponsive to Naproxen and Ibuprofen

A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications

Preventing Childhood Obesity Through Early Guidance

Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure

Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study

Phase 3 Study Evaluating Efficacy and Safety of DSC127 Compared With Vehicle and With Standard-of-care in Diabetic Foot Ulcers

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C

Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients

Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.

Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome

A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis